Table 5.
Characteristics of the long-term survivors
| Characteristics | Missing | |
|---|---|---|
| N (%) | 43 (100) | |
| Age, years, median (range) | 50.1 (26.3–65.1) | |
| < 50 | 21 (49) | |
| 50–60 | 17 (39) | |
| > 60 | 5 (12) | |
| Gender male/female | 21/22 (49/51) | |
| Myeloma subtype | ||
| IgG | 24 (56) | |
| IgA | 5 (11) | |
| IgD | 2 (5) | |
| Light chain | 12 (28) | |
| ISS stage | 5 (12) | |
| I | 18 (42) | |
| II | 13 (30) | |
| III | 7 (16) | |
| Cytogeneticsa | 13 (30) | |
| G-Band analysis normal | 17 (40) | |
| Monosomy 13 | 6 (14) | |
| 14q32 abnormality | 4 (9) | |
| Hyperdiploidy | 3 (7) | |
| Extramedullary diseaseb | 11 (26) | 4 (9) |
| Number of pre-allo-SCT treatment lines | ||
| 1 | 23 (53) | |
| 2 | 14 (33) | |
| 3 | 5 (12) | |
| ≥ 4 | 1 (2) | |
| Novel drugs prior to allo-SCT | ||
| IMID | 6 (14) | |
| PI | 7 (16) | |
| IMID and PI | 11 (26) | |
| None | 19 (44) | |
| Disease status prior to allo-SCT | ||
| sCR/CR | 8 (18) | |
| VGPR/PR | 33 (77) | |
| PD | 2 (5) | |
| Time between diagnosis and allo-SCT, days, median (range) | 329 (137–1543) | |
| Therapy group | ||
| Upfront | 19 (44) | |
| Auto-allo | 20 (47) | |
| Relapse | 4 (9) | |
| Conditioning regimen | ||
| MACc | 20 (47) | |
| CyTBI | 16 (37) | |
| Treo14 | 4 (9.5) | |
| RICd | 23 (53) | |
| FluTBI | 19 (44) | |
| Treo-RIC | 4 (9.5) | |
| GVHD | ||
| Acute GVHD grades 2–4 | 8 (19) | |
| Chronic GVHD at 5 years | 31 (72) |
aOther findings: t(11;14), del1p, trisomy 11 (each with one patient). One with del17p and one with t(4;14), both also had del(13)
bThe presence of plasma cells or plasmacytomas outside the bone marrow
cMAC regimens included CyTBI (cyclophosphamide 60 mg/kg for 2 days and total body irradiation 12 Gy) and Treo14 (treosulfan 14 g/m2 for 3 days and fludarabine 30 mg/m2 for 5 days)
dRIC regimens included FluTBI (fludarabine 30 mg/m2/3 days and total body irradiation 2 Gy) and Treo-RIC (treosulfan 10–12 g/m2 for 3 days and flurarabine 30 mg/m2 for 5 days)
ISS International Staging System, allo-SCT allogeneic hematopoietic stem cell transplantation, IMID immunomodulatory drug, PI proteasome inhibitor, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progressive disease, Upfront-allo allo-SCT performed first line without a previous auto-SCT, auto-allo allo-SCT performed after auto-SCT in first line, relapse allo-SCT performed after relapse, MAC myeloablative conditioning, RIC reduced-intensity conditioning, GVHD graft-versus-host disease